# HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

> **NCT02461121** · PHASE3 · COMPLETED · sponsor: **The Affiliated Hospital of the Chinese Academy of Military Medical Sciences** · enrollment: 156 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **GENETIC:** HLA mismatched stem cell
- **GENETIC:** HLA matched stem cell
- **DRUG:** cyclosporine A
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Ara-C
- **DRUG:** fludarabine
- **DRUG:** anti-lymphocyte globulin
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT02461121
- **Lead sponsor:** The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2015-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02461121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02461121, "HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02461121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*